ABEONA THERAPEUTICS INC. Debt Securities, Available-for-sale, Unrealized Loss
ABEONA THERAPEUTICS INC. (ABEO) reported Debt Securities, Available-for-sale, Unrealized Loss of $79.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-06-30 was $58.00K.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-03-31 was $21.00K, a 68.18% decline year-over-year.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was $34.00K, a 3300.00% increase year-over-year.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-06-30 was -$2.00K.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $22.00K, a 66.67% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $66.00K, a 34.00% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $100.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $79.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $21.00K 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $32.00K derived: sum of 2 quarters · filed 2025-11-12 | $98.00K 10-Q · filed 2025-11-12 | -$15.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $64.00K 10-Q · filed 2025-08-14 | -$49.00K derived: sum of 3 quarters · filed 2026-03-17 | -$48.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | $66.00K 10-Q · filed 2025-05-15 | -$47.00K derived: sum of 2 quarters · filed 2026-03-17 | -$46.00K derived: sum of 3 quarters · filed 2026-03-17 | -$95.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | -$113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$112.00K derived: sum of 2 quarters · filed 2026-03-17 | -$161.00K derived: sum of 3 quarters · filed 2026-03-17 | $22.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$48.00K derived: sum of 2 quarters · filed 2024-11-14 | $135.00K 10-Q · filed 2024-11-14 | $102.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | -$49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $134.00K 10-Q · filed 2024-08-12 | $101.00K derived: sum of 3 quarters · filed 2025-03-20 | $134.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $183.00K 10-Q · filed 2024-05-15 | $150.00K derived: sum of 2 quarters · filed 2025-03-20 | $183.00K derived: sum of 3 quarters · filed 2025-03-20 | $213.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | -$33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $30.00K derived: sum of 3 quarters · filed 2025-03-20 | $66.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $63.00K derived: sum of 2 quarters · filed 2023-11-13 | $99.00K 10-Q · filed 2023-11-13 | $188.00K derived: sum of 4 quarters · filed 2024-03-18 |
| 2023-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $66.00K 10-Q · filed 2023-08-08 | $155.00K derived: sum of 3 quarters · filed 2024-03-18 | $159.00K derived: sum of 4 quarters · filed 2024-03-18 |
| 2023-03-31 | $36.00K 10-Q · filed 2023-05-11 | $125.00K derived: sum of 2 quarters · filed 2024-03-18 | $129.00K derived: sum of 3 quarters · filed 2024-03-18 | |
| 2022-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $93.00K derived: sum of 2 quarters · filed 2024-03-18 | $100.00K 10-K · filed 2024-03-18 | |
| 2022-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.00K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $7.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |